Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety Study of Stereotactic Body Radiotherapy (SBRT) and 177Lu-PSMA617 for the Treatment of Hormone Sensitive, Oligometastatic Prostate Cancer

NCT05079698 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT05079698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05079698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety Study of Stereotactic Body Radiotherapy (SBRT) and 177Lu-PSMA617 for the Treatment of Hormone Sensitive, Oligometastatic Prostate Cancer
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 1, 2021
Completion date
October 31, 2027
Enrollment
29 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer